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METHODS: Patients with 2RCC claims (ICD-9 189.0, 198.0)
receiving sunitinib (n = 244), sorafenib (n = 234) or bevacizumab
(n = 106) were identiﬁed from a large US commercial health
insurance claims database covering over 39 million people
between January 2002–December 2006. Patients were observed
from their ﬁrst angiogenesis inhibitor therapy claim until the last
treatment date. Inpatient, outpatient and pharmacy costs (actual
payments made by health plans) were calculated on a per-patient
per-month (PPPM) basis over the treatment period with costs for
the study drugs reported separately. RESULTS: PPPM costs for
bevacizumab were $5130 higher than PPPM costs for sorafenib
and $3,261 higher than PPPM costs for sunitinib. Additionally,
bevacizumab drug and IV administration costs accounted for
51% of the outpatient costs for those patients. Excluding drug
and administration costs, bevacizumab patients still incurred
higher PPPM outpatient services costs of $3956, compared with
patients receiving sunitinib or sorafenib at $2913 and $2230
respectively. Monthly costs for inpatient services were also higher
for bevacizumab patients ($2467) vs. sunitinib ($1716) and sor-
afenib ($1082) patients. CONCLUSION: RCC patients treated
with bevacizumab incur an additional $39,132–$61,560 total
medical cost increase per patient per year compared to those
treated with sunitinib or sorafenib. The development of more
tolerable and efﬁcacious oral angiogenesis inhibitor therapies
may result in additional cost savings to patients and health care
payers over IV therapies.
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OBJECTIVE: Evidence has shown important therapeutic
outcome differences between dutasteride and ﬁnasteride. The
objective of this study was to assess the differences in economic
costs between these two pharmacologic treatment options within
the ﬁrst year of initiating therapy for Medicare-aged men with
benign prostatic hyperplasia (BPH) from a managed care per-
spective. METHODS: A retrospective analysis of medical and
pharmacy claims was conducted using the Ingenix Lab Rx pro-
prietary research database within a 3-year period from July 1,
2003 to June 30, 2006. Male patients aged  65 years with a
diagnosis of BPH treated with either dutasteride or ﬁnasteride
were identiﬁed. To minimize potential biases that arose from
differential treatment selection, propensity-score-matching
methods were used to identify ﬁnasteride and dutasteride
patients who were similar in terms of their Charlson Comorbid-
ity Index score, Thomson Medstat staging and other background
covariates. Average monthly medical costs were deﬁned as the
total amount charged for BPH-speciﬁc physician visits, inpatient
hospitalizations, outpatient hospital care, emergency department
visits and other ancillary medical services during the follow-up
period for each patient. RESULTS: The matched sample included
a total of 4498 patients. Demographics were comparable
between the two treatment groups with a mean age of 73.6 years.
Patients taking dutasteride had signiﬁcantly lower medical
resource utilization costs per month compared to ﬁnasteride-
treated patients ($122 vs. $173, P < 0.001). The absolute differ-
ence in cost is $51 less per month with dutasteride use. The lower
costs associated with dutasteride appears to be due to the lower
inpatient hospitalization costs ($35.78 vs. $72.29 per month
with ﬁnasteride). CONCLUSION: Medicare-aged patients
treated with dutasteride consumed signiﬁcantly lower medical
resources due to lower inpatient hospitalization expenditure,
showing cost savings of $51 per month per treated patient.
This study supports the growing body of real-world evidence
indicating the clinical and economic beneﬁts associated with
dutasteride.
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OBJECTIVE: To evaluate cost-utility of sevelamer versus
calcium-based phosphate binders (CaPB) in different patient
cohorts and for different dialysis modalities. METHODS: Sys-
tematic literature review was conducted with only studies report-
ing mortality considered. Subgroup analyses were carried out
based on results from one trial (DCOR). Costs of dialysis were
obtained from a recent UK-based study; dosage of drugs was
taken from the DCOR trial, and unit prices from the British
National Formulary; costs were expressed in 2007; utilities
were sourced from the literature. Markov model was developed
for analysis. RESULTS: Six RCTs of sevelamer versus CaPB
reporting all-cause mortality were identiﬁed. No signiﬁcance was
found in meta-analysis: RR = 0.83 [95%CI:0.56–1.17]; differ-
ence in cardiovascular mortality was not signiﬁcant, based on
three RCTs: 0.94 [0.76–1.17]. In the general haemodialysed
population sevelamer cost 6491 more than CaPB after ten
years of treatment, regardless of dialysis modality. In the 65 and
older population, cost of sevelamer was 30,293 higher, while
efﬁcacy was 0.52 QALYs greater; ICER = 58,405. In patients
on peritoneal dialysis, sevelamer cost 17,837 more than CaPB,
with identical efﬁcacy; ICER = 34,389. In patients treated for
at least two years, sevelamer cost 27,266 more, while its
efﬁcacy was 0.41 QALYs higher; ICER = 65,782. In the
65 + population treated for at least two years, cost of sevelamer
was 38,378 higher, while efﬁcacy was 0.70 QALYs greater;
ICER = 55,182. Acceptability curves revealed that probability
of sevelamer being cost-effective at 20,000/QALY ranged 1.2–
13.4%; EVPI was 17–194. With the costs of dialysis excluded,
ICER ranged from 11,944 to 22,543; for all scenarios ICER
diminished with longer time horizons. CONCLUSION: Seve-
lamer is not likely cost-effective, but in the older population it is
more cost-effective in patients on peritoneal dialysis than on
haemodialysis. ICER is relatively high for subgroups, mainly due
to the high cost of dialysis of patients who live longer due to
sevelamer.
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OBJECTIVE: This study assessed costs related to anemia man-
agement in a reference dialysis center. The study also explored
the potential beneﬁt of efﬁciency improvement and costs reduc-
tion with the use of C.E.R.A., a novel continuous erythropoietin
receptor activator that is effective for treating anemia with a once
monthly injection. METHODS: This study was conducted at the
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